DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

Wells Fargo Maintains Overweight on Kezar Life Sciences, Lowers Price Target to $18

Wells Fargo analyst Jim Birchenough maintains Kezar Life Sciences (NASDAQ:KZR) with a Overweight and lowers the price target from $30 to $18.

Benzinga · 03/13/2020 13:15

Wells Fargo analyst Jim Birchenough maintains Kezar Life Sciences (NASDAQ:KZR) with a Overweight and lowers the price target from $30 to $18.